MedTrace Logo

Combination Chemotherapy and Bone Marrow Transplant in Treating Patients With Refractory or Recurrent Ovarian Cancer

NCT00002474 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2013-05-30

No results posted yet for this study

Summary

RATIONALE: Drugs used in chemotherapy, such as cyclophosphamide, carboplatin, and mitoxantrone, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving chemotherapy with autologous bone marrow transplant may allow the doctor to give higher doses of chemotherapy and kill more tumor cells.

PURPOSE: This phase II trial is studying how well chemotherapy and autologous bone marrow transplant work in treating patients with refractory or recurrent ovarian cancer.

Conditions

Interventions

DRUG

carboplatin

DRUG

cyclophosphamide

DRUG

mitoxantrone hydrochloride

PROCEDURE

autologous bone marrow transplantation

PROCEDURE

bone marrow ablation with stem cell support

Sponsors & Collaborators

  • Loyola University

    lead OTHER

Principal Investigators

  • Patrick J. Stiff, MD · Loyola University

Study Design

Purpose
TREATMENT
Masking
NONE

Eligibility

Max Age
64 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
1991-02-28
Completion
2005-10-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00002474 on ClinicalTrials.gov